Jennifer M Yeh1, Kathryn P Lowry2, Clyde B Schechter3, Lisa R Diller4, Oguzhan Alagoz5, Gregory T Armstrong6, John M Hampton5, Wendy Leisenring7, Qi Liu8, Jeanne S Mandelblatt9, Diana L Miglioretti10, Chaya S Moskowitz11, Kevin C Oeffinger12, Amy Trentham-Dietz5, Natasha K Stout13. 1. Harvard Medical School and Boston Children's Hospital, Boston, Massachusetts (J.M.Y.). 2. University of Washington, Seattle, Washington (K.P.L.). 3. Albert Einstein College of Medicine, Bronx, New York (C.B.S.). 4. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts (L.R.D.). 5. University of Wisconsin-Madison, Madison, Wisconsin (O.A., J.M.H., A.T.). 6. St. Jude Children's Research Hospital, Memphis, Tennessee (G.T.A.). 7. University of Wisconsin-Madison, Fred Hutchinson Cancer Research Center, Seattle, Washington (W.L.). 8. University of Alberta, Edmonton, Alberta, Canada (Q.L.). 9. Georgetown University, Washington, DC (J.S.M.). 10. University of California Davis School of Medicine, Davis, California (D.L.M.). 11. Memorial Sloan Kettering Cancer Center, New York, New York (C.S.M.). 12. Duke Cancer Institute, Durham, North Carolina (K.C.O.). 13. Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (N.K.S.).
Abstract
BACKGROUND: Surveillance with annual mammography and breast magnetic resonance imaging (MRI) is recommended for female survivors of childhood cancer treated with chest radiation, yet benefits, harms, and costs are uncertain. OBJECTIVE: To compare the benefits, harms, and cost-effectiveness of breast cancer screening strategies in childhood cancer survivors. DESIGN: Collaborative simulation modeling using 2 Cancer Intervention and Surveillance Modeling Network breast cancer models. DATA SOURCES: Childhood Cancer Survivor Study and published data. TARGET POPULATION: Women aged 20 years with a history of chest radiotherapy. TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Annual MRI with or without mammography, starting at age 25, 30, or 35 years. OUTCOME MEASURES: Breast cancer deaths averted, false-positive screening results, benign biopsy results, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: Lifetime breast cancer mortality risk without screening was 10% to 11% across models. Compared with no screening, starting at age 25 years, annual mammography with MRI averted the most deaths (56% to 71%) and annual MRI (without mammography) averted 56% to 62%. Both strategies had the most screening tests, false-positive screening results, and benign biopsy results. For an ICER threshold of less than $100 000 per quality-adjusted life-year gained, screening beginning at age 30 years was preferred. RESULTS OF SENSITIVITY ANALYSIS: Assuming lower screening performance, the benefit of adding mammography to MRI increased in both models, although the conclusions about preferred starting age remained unchanged. LIMITATION: Elevated breast cancer risk was based on survivors diagnosed with childhood cancer between 1970 and 1986. CONCLUSION: Early initiation (at ages 25 to 30 years) of annual breast cancer screening with MRI, with or without mammography, might reduce breast cancer mortality by half or more in survivors of childhood cancer. PRIMARY FUNDING SOURCE: American Cancer Society and National Institutes of Health.
BACKGROUND: Surveillance with annual mammography and breast magnetic resonance imaging (MRI) is recommended for female survivors of childhood cancer treated with chest radiation, yet benefits, harms, and costs are uncertain. OBJECTIVE: To compare the benefits, harms, and cost-effectiveness of breast cancer screening strategies in childhood cancer survivors. DESIGN: Collaborative simulation modeling using 2 Cancer Intervention and Surveillance Modeling Network breast cancer models. DATA SOURCES: Childhood Cancer Survivor Study and published data. TARGET POPULATION: Women aged 20 years with a history of chest radiotherapy. TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Annual MRI with or without mammography, starting at age 25, 30, or 35 years. OUTCOME MEASURES: Breast cancer deaths averted, false-positive screening results, benign biopsy results, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: Lifetime breast cancer mortality risk without screening was 10% to 11% across models. Compared with no screening, starting at age 25 years, annual mammography with MRI averted the most deaths (56% to 71%) and annual MRI (without mammography) averted 56% to 62%. Both strategies had the most screening tests, false-positive screening results, and benign biopsy results. For an ICER threshold of less than $100 000 per quality-adjusted life-year gained, screening beginning at age 30 years was preferred. RESULTS OF SENSITIVITY ANALYSIS: Assuming lower screening performance, the benefit of adding mammography to MRI increased in both models, although the conclusions about preferred starting age remained unchanged. LIMITATION: Elevated breast cancer risk was based on survivors diagnosed with childhood cancer between 1970 and 1986. CONCLUSION: Early initiation (at ages 25 to 30 years) of annual breast cancer screening with MRI, with or without mammography, might reduce breast cancer mortality by half or more in survivors of childhood cancer. PRIMARY FUNDING SOURCE: American Cancer Society and National Institutes of Health.
Authors: Timothy Best; Dalin Li; Andrew D Skol; Tomas Kirchhoff; Sarah A Jackson; Yutaka Yasui; Smita Bhatia; Louise C Strong; Susan M Domchek; Katherine L Nathanson; Olufunmilayo I Olopade; R Stephanie Huang; Thomas M Mack; David V Conti; Kenneth Offit; Wendy Cozen; Leslie L Robison; Kenan Onel Journal: Nat Med Date: 2011-07-24 Impact factor: 53.440
Authors: Wendy Landier; Smita Bhatia; Debra A Eshelman; Katherine J Forte; Teresa Sweeney; Allison L Hester; Joan Darling; F Daniel Armstrong; Julie Blatt; Louis S Constine; Carolyn R Freeman; Debra L Friedman; Daniel M Green; Neyssa Marina; Anna T Meadows; Joseph P Neglia; Kevin C Oeffinger; Leslie L Robison; Kathleen S Ruccione; Charles A Sklar; Melissa M Hudson Journal: J Clin Oncol Date: 2004-12-02 Impact factor: 44.544
Authors: Oguzhan Alagoz; Donald A Berry; Harry J de Koning; Eric J Feuer; Sandra J Lee; Sylvia K Plevritis; Clyde B Schechter; Natasha K Stout; Amy Trentham-Dietz; Jeanne S Mandelblatt Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583
Authors: Jeanne S Mandelblatt; Aimee M Near; Diana L Miglioretti; Diego Munoz; Brian L Sprague; Amy Trentham-Dietz; Ronald Gangnon; Allison W Kurian; Harald Weedon-Fekjaer; Kathleen A Cronin; Sylvia K Plevritis Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583
Authors: Ronald E Gangnon; Natasha K Stout; Oguzhan Alagoz; John M Hampton; Brian L Sprague; Amy Trentham-Dietz Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583
Authors: Debra L Monticciolo; Mary S Newell; Linda Moy; Bethany Niell; Barbara Monsees; Edward A Sickles Journal: J Am Coll Radiol Date: 2018-01-19 Impact factor: 5.532
Authors: Paul Craig Nathan; Christopher Keller Daugherty; Kristen Elizabeth Wroblewski; Mackenzie Louise Kigin; Tom Vernon Stewart; Fay Jarmila Hlubocky; Eva Grunfeld; Marie Elisabeth Del Giudice; Leigh-Anne Evelyn Ward; James Mahlon Galliher; Kevin Charles Oeffinger; Tara Olive Henderson Journal: J Cancer Surviv Date: 2013-03-08 Impact factor: 4.442
Authors: Tara O Henderson; Chaya S Moskowitz; Joanne F Chou; Angela R Bradbury; Joseph Phillip Neglia; Chau T Dang; Kenan Onel; Danielle Novetsky Friedman; Smita Bhatia; Louise C Strong; Marilyn Stovall; Lisa B Kenney; Dana Barnea; Elena Lorenzi; Sue Hammond; Wendy M Leisenring; Leslie L Robison; Gregory T Armstrong; Lisa R Diller; Kevin C Oeffinger Journal: J Clin Oncol Date: 2015-12-23 Impact factor: 44.544
Authors: Lindsay M Morton; Joshua N Sampson; Gregory T Armstrong; Ting-Huei Chen; Melissa M Hudson; Eric Karlins; Casey L Dagnall; Shengchao Alfred Li; Carmen L Wilson; Deo Kumar Srivastava; Wei Liu; Guolian Kang; Kevin C Oeffinger; Tara O Henderson; Chaya S Moskowitz; Todd M Gibson; Diana M Merino; Jeannette R Wong; Sue Hammond; Joseph P Neglia; Lucie M Turcotte; Jeremy Miller; Laura Bowen; William A Wheeler; Wendy M Leisenring; John A Whitton; Laurie Burdette; Charles Chung; Belynda D Hicks; Kristine Jones; Mitchell J Machiela; Aurelie Vogt; Zhaoming Wang; Meredith Yeager; Geoffrey Neale; Matthew Lear; Louise C Strong; Yutaka Yasui; Marilyn Stovall; Rita E Weathers; Susan A Smith; Rebecca Howell; Stella M Davies; Gretchen A Radloff; Kenan Onel; Amy Berrington de González; Peter D Inskip; Preetha Rajaraman; Joseph F Fraumeni; Smita Bhatia; Stephen J Chanock; Margaret A Tucker; Leslie L Robison Journal: J Natl Cancer Inst Date: 2017-11-01 Impact factor: 13.506
Authors: Jennifer M Yeh; Zachary J Ward; Aeysha Chaudhry; Qi Liu; Yutaka Yasui; Gregory T Armstrong; Todd M Gibson; Rebecca Howell; Melissa M Hudson; Kevin R Krull; Wendy M Leisenring; Kevin C Oeffinger; Lisa Diller Journal: JAMA Oncol Date: 2020-03-01 Impact factor: 31.777
Authors: Morgan Lamberg; Andrea Rossman; Alexandra Bennett; Sabrina Painter; Rachel Goodman; James MacLeod; Ragasnehith Maddula; David Rayan; Krishna Doshi; Alexander Bick; Simone Bailey; Sherry-Ann Brown Journal: Curr Atheroscler Rep Date: 2022-04-19 Impact factor: 5.113
Authors: Kathryn P Lowry; H Amarens Geuzinge; Natasha K Stout; Oguzhan Alagoz; John Hampton; Karla Kerlikowske; Harry J de Koning; Diana L Miglioretti; Nicolien T van Ravesteyn; Clyde Schechter; Brian L Sprague; Anna N A Tosteson; Amy Trentham-Dietz; Donald Weaver; Martin J Yaffe; Jennifer M Yeh; Fergus J Couch; Chunling Hu; Peter Kraft; Eric C Polley; Jeanne S Mandelblatt; Allison W Kurian; Mark E Robson Journal: JAMA Oncol Date: 2022-04-01 Impact factor: 33.006
Authors: Amy Trentham-Dietz; Oguzhan Alagoz; Christina Chapman; Xuelin Huang; Jinani Jayasekera; Nicolien T van Ravesteyn; Sandra J Lee; Clyde B Schechter; Jennifer M Yeh; Sylvia K Plevritis; Jeanne S Mandelblatt Journal: PLoS Comput Biol Date: 2021-06-17 Impact factor: 4.475
Authors: Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Grace O'Brien; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Melissa M Hudson; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Paul C Nathan; Joseph P Neglia; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout Journal: J Natl Cancer Inst Date: 2022-02-07 Impact factor: 11.816